Type 1 Diabetes (T1D)
Type 1 Diabetes Introduction
- Nature of the Disease:Type 1 diabetes (T1D) is an autoimmune disease.
- Pathological Mechanism:The immune system attacks and destroys the insulin-producing beta-cells in the pancreas, preventing the body from secreting sufficient insulin.
- Typical Onset Age:T1D is most commonly diagnosed in children and adolescents, but it can develop at any age.
- Primary Impact:Due to the lack of insulin, patients must rely on exogenous insulin therapy to maintain blood glucose balance.
Type 1 Diabetes
It originates from the autoimmune system attacking the insulin-secreting beta cells in the pancreas, leading to insufficient insulin secretion. It typically develops during adolescence, and the current main treatment relies on insulin injections.。
Pipeline
Product
(Development Code)
(Development Code)
Indication
Preclinical
Phase I
Phase II
Phase III
PS1(PS-002)
Type 1 Diabetes
PS1 alone and in combination can treat TD via immune and endocrine modulation
Excess nutrients
PS1 treatment
Type 1 Diabetes Market Size (2023-2034)
Market Value Projection in USD Billion
Value (Billion USD)
Swipe horizontally to view full chart ➔
80
60
40
20
0
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
The global type 1 diabetes (T1D) market size was approximately USD 34.87 billion in 2024 and is projected to reach about USD 74.03 billion by 2034, demonstrating a compound annual growth rate (CAGR) of 7.82% during the period from 2024 to 2034.
Source: Precedence Research
